Jinmin Miao
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
Publications
64
Citations
1,564
Est. group size
~10
Recurring co-author estimate
Active years
37
Publishing since 1990
Jinmin Miao's research focuses on protein tyrosine phosphatases (enzymes that remove phosphate groups from proteins, a key step in cell signaling) and their role in cancer, particularly SHP1, SHP2, and PTPN22. Work spans drug discovery approaches like targeted protein degradation and small-molecule inhibitors, studying how these enzymes affect processes such as tumor growth, immune cell infiltration, blood cell development, and cancer drug resistance. Studies use mouse models, structural biology, and cell-based assays to understand and target KRAS-related and phosphatase-driven signaling pathways in cancers including breast, pancreatic, colorectal, and ovarian cancer.
Publication output was low and sporadic from 2017-2021, then increased notably from 2022-2023, with a sharp spike in 2024 before dropping again in 2025-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Author response: Synergistic effects of deleting the tyrosine phosphatases Shp1 and Shp2 on megakaryopoiesis and thrombopoiesis in mice
2026
- Synergistic effects of deleting the tyrosine phosphatases Shp1 and Shp2 on megakaryopoiesis and thrombopoiesis in mice
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Protein Tyrosine Phosphatase 4A1 (PTP4A1) Regulates Early Events in Colorectal Cancer Intraperitoneal Dissemination in the Aged Male Host
Aging and Cancer · 2025
- Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation
ChemMedChem · 2024
- Structure-activity relationship studies and design of a PTPN22 inhibitor with enhanced isozyme selectivity and cellular efficacy
European Journal of Medicinal Chemistry · 2024
- 40P Small molecule inhibitor HI-TOPK-032 improves NK-92MI cells infiltration into ovarian tumors
ESMO Open · 2024
- Abstract 1969: Off-target autophagy inhibition by SHP2 allosteric inhibitors and therapeutic implications for aberrant RAS-driven cancers
Cancer Research · 2024
- Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation
UNC Libraries · 2024
- Structure-Activity Relationship Studies and Design of a Ptpn22 Inhibitor with Enhanced Isozyme Selectivity and Cellular Efficacy
SSRN Electronic Journal · 2024
- Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity
Molecules · 2023
- Driving axon regeneration by orchestrating neuronal and non-neuronal innate immune responses via the IFNγ-cGAS-STING axis
Neuron · 2022
- The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors
Nature Communications · 2021
- SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer
Oncogene · 2020
- Targeting FGFR signalling to disrupt cellular cross-talk in pancreatic cancer
Pancreatology · 2020
- Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation
Nature Communications · 2019
- Nature Communications×2
- Cancer Research Communications×2
- Neuron×1
- Oncogene×1
- Angewandte Chemie International Edition×1
- Frederick Nguele Meke
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Qinglin Li
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Nam Chu
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Darien E. Reed
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Li‐Fan Zeng
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile